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Background:  Oral  polio  vaccine  (OPV)  and  rotavirus  vaccine  (RV)  exhibit  poorer  performance  in  low-
income  settings  compared  to  high-income  settings.  Prior  studies  have  suggested  an  inhibitory  effect  of
concurrent  non-polio  enterovirus  (NPEV)  infection,  but the  impact  of other  enteric  infections  has  not
been  comprehensively  evaluated.
Methods:  In urban  Bangladesh,  we  tested  stools  for a  broad  range  of  enteric  viruses,  bacteria,  parasites,
and  fungi  by quantitative  PCR  from  infants  at weeks  6 and 10 of  life,  coincident  with  the  ﬁrst  OPV  and
RV  administration  respectively,  and examined  the  association  between  enteropathogen  quantity  and
subsequent  OPV  serum  neutralizing  titers,  serum  rotavirus  IgA,  and  rotavirus  diarrhea.
Results:  Campylobacter  and enterovirus  (EV)  quantity  at the  time  of administration  of  the  ﬁrst dose  of  OPV
was  associated  with  lower  OPV1-2  serum  neutralizing  titers,  while  enterovirus  quantity  was also  associ-
ated with  diminished  rotavirus  IgA  (−0.08 change  in  log  titer  per  tenfold  increase  in  quantity;  P  =  0.037),
failure  to seroconvert  (OR 0.78,  95%  CI: 0.64–0.96;  P = 0.022),  and breakthrough  rotavirus  diarrhea  (OR
1.34,  95%  CI:  1.05–1.71;  P  = 0.020)  after  adjusting  for potential  confounders.  These  associations  were  not
observed  for  Sabin  strain  poliovirus  quantity.
Conclusion:  In  this  broad  survey  of  enteropathogens  and  oral  vaccine  performance  we ﬁnd a particu-
lar  association  between  EV  carriage,  particularly  NPEV,  and  OPV  immunogenicity  and  RV protection.
Strategies  to reduce  EV  infections  may  improve  oral  vaccine  responses.
ClinicalTrials.gov  Identiﬁer:  NCT01375647.. IntroductionThe primary oral vaccines in use globally, OPV and RV, have
oorer efﬁcacy in infants in low-income settings compared to
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olio enterovirus; EV, enterovirus; PROVIDE, Performance of Rotavirus and Oral
olio Vaccines in Developing Countries; IPV, inactivated poliovirus vaccine; EAEC,
nteroaggregative E. coli; EIEC, enteroinvasive E. coli; EPEC, enteropathogenic E. coli;
TEC, enterotoxigenic E. coli; STEC, Shiga-toxin producing E. coli; TAC, TaqMan Array
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middle- to high-income countries [1,2]. This observation was  ﬁrst
noted with the introduction of OPV in the 1960s and 1970s
[3,4]. Subsequent studies have implicated several factors, including
high maternal antibodies, concurrent breastfeeding, malnutri-
tion, environmental enteropathy, prior or concurrent diarrhea,
co-administration of other oral vaccines, or the presence of other
enteric infections [5–10]. Because these factors will co-exist in
a given setting to varying degrees, documenting the predom-
inance of a single factor such as enteric infections has been
difﬁcult. A recent meta-analysis of available studies, however, did
demonstrate reduced odds of OPV seroconversion with concurrent
non-polio enterovirus (NPEV) infection at the time of administra-
tion, particularly for type 1 OPV [11]. Notably, these studies were
derived from the 1960s–1970s when the milieu of these other risk
factors likely differed, and viral culture was  standard practice to
detect NPEV. Thus the impact of enteric infections on OPV and RV
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as not been re-visited in recent studies using modern molecular
iagnostic techniques.
In the present-day Bangladeshi slum, exposure to enteric
athogens is ubiquitous from birth. Speciﬁcally, upon testing for
 broad range of enteropathogens with molecular methods in
irth cohorts, we have detected an average of more than 2 infec-
ions within the ﬁrst month of life [12], particularly Campylobacter
nd Escherichia coli pathotypes. In this study we used molecu-
ar methods, which included all of the major viruses including
nteroviruses, bacteria, protozoa, helminths, and fungi. We  utilized
 quantitative, singleplex, real-time PCR TaqMan Array Card plat-
orm that we have described previously [13,14]. We  analyzed stools
ollected prior to the ﬁrst administration of OPV and RV at weeks
 and 10 respectively to allow for a comprehensive, quantitative
xamination of concurrent enteric infections and subsequent oral
accine performance.
. Materials and methods
.1. Study design and participants
This study was part of the “Performance of Rotavirus and Oral
olio Vaccines in Developing Countries (PROVIDE)” which fol-
owed infants from birth to 24 months of age in the urban slum
rea of Mirpur in Dhaka, Bangladesh to investigate the causes
f underperformance of OPV and Rotarix in low-income settings
15]. In total 700 infants were recruited from November 2010
o August 2012. TAC testing was performed on subsets as indi-
ated in Table 1. Infants were randomized to receive either the
angladeshi Expanded Program on Immunization vaccine regimen
f trivalent OPV (GlaxoSmithKline) at 6, 10, 14, and 38 weeks of age,
ersus substituted inactivated poliovirus vaccine (IPV; IMOVAX,
anoﬁ Pasteur) at 38 weeks. Infants in both arms were indepen-
ently randomized to receive Rotarix vaccine (GlaxoSmithKline)
r not at 10 and 17 weeks of age. Stool samples were collected
ither at the clinic or the participant’s home before vaccinations
nd delivered to our lab while maintaining cold chain within 6 h
f collection and stored in −80 ◦C until further processing. We
ested by TAC pre-6 week vaccination stools from a subset of 339
nfants (166 female, 173 male), who were chosen randomly from
he cohort. From this subset, we additionally tested stools col-
ected at week 10 prior to the ﬁrst dose of Rotarix from the 159
hildren who received rotavirus vaccine per protocol. Infants were
ollowed via twice-weekly home visits from week 18–52 for inci-
ent diarrhea and diarrheal stool specimens were collected and
ested for rotavirus by ELISA (ProSpecT, Oxoid, UK). Informed con-
ent was obtained from all participants’ parents or guardians. This
tudy was approved by the Institutional Review Committee and the
nstitutional Ethical Committee at the International Centre for Diar-
hoeal Disease Research, Bangladesh (icddr,b) and the Institutional
eview Boards at the University of Vermont and the University of
irginia.
able 1
chematic of this sub-study within PROVIDE. Infants underwent stool enteropathogen te
Week of life 6 10 14 
Vaccination tOPV tOPV tOPV
Rotarix 
OPV  sub-study TAC of stool prior
to tOPV (n = 339)
Culture o
EV prior
Rotarix sub-study TAC of stool prior to
Rotarix (n = 159); qRT-PCR
for pan-EV and Sabin
strains (n = 277)4 (2016) 3068–3075 3069
2.2. Vaccine antibody titers
Sera obtained from infants at 6 and 18 weeks of age were
shipped on dry ice from Bangladesh to the Centers for Disease Con-
trol in Atlanta, USA for neutralizing antibody assays for poliovirus
serotype 1, 2, and 3 (log 2 based titer) which were performed
according to World Health Organization methods [16]. Rotavirus
plasma IgA was  measured as described previously [17]. OPV sero-
conversion was deﬁned as both a week 18 neutralizing antibody
titer greater than 2.83 (log 2 based titer) and a change in the log
titer between weeks 6 and 18 of at least 3 (to account for decay
in maternally-transferred antibody from week 6 to week 18 with a
half-life of 4 weeks). Rotavirus serconversion was deﬁned as both
a serum rotavirus IgA greater than 20 U/mL at week 18 and a titer
of less than 20 U/mL at week 6.
2.3. RNA and DNA extraction from stool
RNA was  extracted from stool using a slightly modiﬁed proto-
col of the QIAamp Viral RNA Mini Kit (Qiagen, Gaithersburg, MD)
[18]. Brieﬂy, 100–200 mg  of stool specimen was  added to 1 ml of
0.89% NaCl solution in a 2 ml  screw cap tube and vortexed. The sus-
pension was centrifuged at 4000 × g for 20 min  then 140 l of the
supernatant was  added to 560 l of Buffer AVL containing carrier
RNA and 1 l of bacteriophage MS2  (approximately 2 × 106 copies,
ATCC 15597B1; American Type Culture Collection, Manassas, VA)
per sample to serve as an extraction and ampliﬁcation control. The
suspension was mixed thoroughly then incubated at room tem-
perature for 10 min. After incubation, 560 l of ethanol was  added
then mixed by pulse-vortexing for 15 s. An aliquot of 630 l was
applied to the QIAamp Mini column and then followed the man-
ufacturer’s recommended protocol supplied with the kit. The RNA
was stored with 60 l of RNA Storage Solution (Ambion, Foster City,
CA) in −80 ◦C until testing. DNA was extracted using a modiﬁed
QIAamp DNA Stool Mini Kit protocol (Qiagen, Gaithersburg, MD)
[19]. Brieﬂy, 1.4 ml  of the lysis buffer ASL with extrinsic control,
phocine herpes virus (PhHV), was  added to the 200 mg  of stool,
then the suspension was pretreated by bead beating with glass
beads (Sigma–Aldrich, St. Louis, MO)  for 2 min  followed by incuba-
tion for 7 min  at 95 ◦C before proceeding with the extraction as per
manufacturer’s protocol. DNA was stored in −80 ◦C until testing.
2.4. Molecular diagnostics
Custom-developed TaqMan Array Cards (TAC) were utilized for
detection of infections in stool. Brieﬂy, RNA and DNA were com-
bined and tested using the methodology, master mix, and cycling
conditions previously described on a Viia7 platform (Life Technolo-
gies, South San Francisco, CA) [13]. Validation of the platform has
been described [14]. We  tested for alphabetically, the following
infections using those previously described assays with additions
as speciﬁed: adenovirus 40/41 [20], Aeromonas spp. [21], Ancy-
lostoma duodenale [22], Ascaris lumbricoides, astrovirus, Bacteroides
sting and immunologic and efﬁcacy follow-up at the time points indicated.
17 18 18–52
Rotarix
f stool for
 to tOPV
Outcomes: OPV1-3 serum
neutralizing titer and
seroconversion
Outcomes: Serum rotavirus
IgA and seroconversion
Outcome:
Rotavirus diarrhea
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ragilis [23], Campylobacter spp. [24], Clostridium difﬁcile, Cryp-
osporidium hominus/parvum [25], Cyclospora cayetanensis [26],
ystoisospora belli [27], Encephalitozoon intestinalis [28], Entamoeba
istolytica, Enterocytozoon bieneusi [28], enteroaggregative E. coli
EAEC), enteroinvasive E. coli (EIEC)/Shigella,  enteropathogenic
. coli (EPEC), enterotoxigenic E.coli (ETEC), pan-enterovirus [29],
iardia lamblia, Helicobacter pylori, Mycobacterium tuberculosis [30],
ecator americanus [22], norovirus GI [31], norovirus GII, rotavirus,
almonella spp., sapovirus, Shiga-toxin producing E. coli (STEC),
trongyloides stercoralis [32]), Trichuris trichiura and Vibrio cholerae
21]. Virulence genes were used to deﬁne the E. coli pathotypes as
ollows: aaiC and/or aatA for EAEC, ipaH for EIEC/Shigella, ST and/or
T for ETEC, eae with or without bfpA for EPEC, and stx1 and/or
tx2 for STEC. Ampliﬁcation after threshold cycle (Ct) above 35 was
onsidered negative. In addition, all available 10 week stool from
hildren who received RV per protocol and were followed until at
east one year of age were tested by the cognate pan-EV RT-qPCR
n plates. Brieﬂy, 0.8 l Ag-Path One-Step RT enzyme (Life Tech-
ologies, South San Francisco, CA), 10 l Ag-Path 2× buffer, 7.2 l
uclease free water, 1 l of enterovirus assay (primer and probe
ix) and 1 l of RNA was tested in 20 l reaction and run on a
FX cycler (Bio-Rad, Ventura, CA) with cycling conditions: 45 ◦C for
0 min, 95 ◦C for 10 min, and 45 cycles of 95 ◦C for 15 s and 60 ◦C for
 min. To further describe EV infections in these stools, we utilized
 multiplex RT-qPCR assay to identify Sabin strain polioviruses [33].
.5. Viral culture
Stools from children prior to the 14 week OPV administra-
ion underwent viral culture for polio and NPEV according to the
ethodologies of the World Health Organization’s Polio laboratory
anual (4th edition) [16]. Brieﬂy, stool cultures that were positive
n RD cell lines but negative on LB20 cell lines were identiﬁed as
PEV.
.6. Statistical analysis
To estimate associations between pathogen quantity and vac-
ine titers, seroconversion, and breakthrough rotavirus diarrhea,
inear regression was used for continuous outcomes and logistic
egression for binary outcomes. In all cases, antibody titers were log
ransformed. For the linear regression analysis of OPV and rotavirus
iters, baseline titers obtained prior to OPV administration at week
 were included as covariates. For all analyses, pathogen burden
as deﬁned as the number of non-enterovirus enteropathogens
etected in a stool. Additional covariates, including gender, income,
reatment of drinking water, weight-for-age Z score at 10 weeks,
umber of episodes of diarrhea through 6 weeks of age, weeks of
xclusive breastfeeding through week 18, and serum zinc level at
8 weeks were included in the adjusted regression models based on
odel ﬁt as determined by the Akaike Information Criterion (AIC).
f the AIC was similar between candidate models, covariates were
etained. Other covariates considered but not included were Vita-
in  D level at 18 weeks, maternal education, length-for-age Z score
t 10 weeks, and retinol binding protein at 18 weeks. The Wilcoxon
ank sum test was used to compare antibody titers and pathogen
urden between groups. All P-values were considered statistically
igniﬁcant at a level of 0.05. All analyses were performed in R 3.2.2
R Foundation for Statistical Computing, Vienna, Austria [2015]).
. Results.1. Enteric infections at the time of vaccination
TAC was performed on stool samples from 339 randomly
elected infants at week 6 of life prior to the ﬁrst OPV administration4 (2016) 3068–3075
and, for the 159 of these infants who  received RV per protocol, at
week 10 prior to the ﬁrst RV administration. The mean number
of pathogens detected in the pre-vaccination stool specimens was
1.7 ± 1.4 pathogens at week 6 and 2.4 ± 1.4 pathogens at week 10
(P < 0.001). At least 1 infection was detected in 82.0% of week 6 and
96.9% of week 10 stools, and multiple infections were abundant
(48.7% and 73.0% had 2 or more pathogens at the two time points,
respectively). The speciﬁc pathogens are shown in Fig. 1.
3.2. Speciﬁc enteric infections and their association with OPV
immunogenicity
An association was  observed between the number of pathogens
detected at the time of the ﬁrst OPV administration (6 weeks) and
a reduced OPV serum neutralizing titer (18 weeks) for all 3 types,
however after adjusting for potential confounders, statistical sig-
niﬁcance was  seen only for P2 (Table 2). That said, in the subset
tested by TAC, seroconversion to P2 was  high (95% vs. 86% and 83%
for P1 and P3). Since most individual infections were rare at these
early time points, and to avoid spurious associations, we  exam-
ined the association between those pathogens with at least a 10%
prevalence (Campylobacter, EAEC, EV) and OPV immunogenicity
using multivariable linear and logistic regression. Pathogens sig-
niﬁcantly associated with lower OPV serum neutralizing titer were
Campylobacter and EV for P1 and P2 (Table 2). Fig. 2 illustrates these
data by showing EV quantity versus OPV1-3 serum neutralizing
titer.
All pan-EV TAC positive stools (121/339 (35.7%)) were further
tested for OPV1-3 by qRT-PCR, of which only 8/121 (6.6%) were
positive, suggesting this EV effect on OPV was due to NPEV and not
circulating Sabin viruses. The association between OPV  serum neu-
tralizing antibody and NPEV carriage was also seen by stool culture
prior to OPV administration at week 14 (mean P1 titer 7.83 ± 3.17 in
NPEV positive vs. 9.14 ± 2.41 in NPEV negative, P = 0.021; mean P2
titer 9.61 ± 1.75 vs. 9.89 ± 1.40, P = 0.066; mean P3 titer 6.79 ± 3.12
vs. 8.32 ± 2.70, P < 0.001).
3.3. Speciﬁc enteric infections and their association with Rotarix
immunogenicity and efﬁcacy
We  then determined the association between enteric infections
at the time of the ﬁrst dose of RV at week 10 and serum rotavirus IgA
measured post-RV at week 18. In the subset of 159 infants tested
by TAC at week 6 who  received RV per protocol, TAC was  also per-
formed on week 10 stools, and EV quantity was again associated
with reduced rotavirus IgA titer, whereas no other enteric infection
exhibited a signiﬁcant association (Table 3). To further investigate
the association between enterovirus and rotavirus vaccine perfor-
mance, we tested available week 10 stools from the remaining
infants who  received RV per protocol (n = 277) for EV by PCR.
These infants were followed from weeks 18–52 of life to identify
episodes of rotavirus diarrhea conﬁrmed by enzyme immunoas-
say. 45 of 277 had at least one episode of rotavirus diarrhea during
this time period. In the adjusted analysis, EV infection at week 10
was associated with increased odds of breakthrough rotavirus diar-
rhea (Table 4, OR 1.34 per tenfold increase in EV quantity; P = 0.020;
Supplemental Fig. 1A). To better understand the identity of these
EV, we  tested each EV PCR-positive stool by PCR for Sabin strain
poliovirus. EV was detected in 221 of 277 stools, and 150 of 221
(67.9%) were positive for OPV1-3, presumably reﬂecting shedding
of the week 6 OPV dose. However, OPV1-3 quantity was not sig-
niﬁcantly associated with impaired RV immunogenicity (Table 4)
or efﬁcacy (Table 4 and Supplemental Fig. 1B), suggesting that the
association between EV and vaccine performance was  speciﬁc to
NPEV. Finally, since EV infection may  simply be a marker for other
risk factors associated with breakthrough rotavirus diarrhea, we
M. Taniuchi et al. / Vaccine 34 (2016) 3068–3075 3071
Fig. 1. Prevalence of enteric infections detected by quantitative PCR in week 6 (n = 339) and 10 (n = 159) pre-vaccination stool specimens. Pre-vaccination stool specimens
were  collected at the time points indicated and assayed for enteropathogens by TAC. All tested helminths and M.  tuberculosis were exceedingly rare (0–3%) and are not shown.
All  infections were tested by TAC except OPV; OPV prevalence is overlaid on enterovirus prevalence with light blue for week 6 and light red for week 10).
Table 2
Association between pathogen burden as well as speciﬁc pathogen quantities and the week 18 OPV serum neutralizing titer in stools collected prior to ﬁrst OPV dose (n = 339).
For  each serotype, results were adjusted for gender, income, treatment of drinking water, weight-for-age Z score at week 10, and number of diarrheal episodes through 6
weeks  of age using multivariable linear regression.
Serotype
(mean titer ± SD)
Pathogen Change in titer Seroconversion
Crudea Adjustedb Crudea Adjustedb
Change in log
polio titer
P value Change in log
polio titerb
P value Odds ratio
(95% CI)
P value Odds ratio
(95% CI)
P value
P1 (9.01 ± 2.52) Total pathogen burdenc −0.15 0.111 −0.19 0.055 0.90 (0.73–1.10) 0.296 0.84 (0.67–1.05) 0.134
Campylobacter spp. −0.27 0.044 −0.29 0.036 0.82 (0.63–1.06) 0.133 0.81 (0.62–1.05) 0.114
Enterovirus −0.29 0.009 −0.28 0.014 0.80 (0.64–1.02) 0.069 0.81 (0.63–1.04) 0.097
EAEC  0.14 0.069 0.15 0.060 1.31 (1.02–1.67) 0.032 1.33 (1.03–1.72) 0.031
P2  (9.87 ± 1.44) Total pathogen burdenc −0.21 <0.001 −0.18 0.001 0.61 (0.45–0.81) <0.001 0.67 (0.49–0.91) 0.011
Campylobacter spp. −0.23 0.003 −0.20 0.011 0.71 (0.50–1.01) 0.060 0.77 (0.52–1.16) 0.211
Enterovirus −0.23 <0.001 −0.22 <0.001 0.51 (0.36–0.74) <0.001 0.53 (0.36–0.77) <0.001
EAEC  −0.07 0.095 −0.05 0.298 0.75 (0.58–0.96) 0.021 0.79 (0.61–1.03) 0.083
P3  (8.15 ± 2.79) Total pathogen burdenc −0.21 0.046 −0.17 0.113 0.84 (0.70–1.02) 0.073 0.88 (0.72–1.08) 0.227
Campylobacter spp. −0.30 0.043 −0.22 0.145 0.78 (0.62–0.99) 0.040 0.83 (0.65–1.07) 0.143
Enterovirus −0.19 0.122 −0.14 0.264 0.83 (0.67–1.04) 0.100 0.87 (0.69–1.09) 0.226
EAEC  −0.04 0.624 −0.03 0.723 0.95 (0.81–1.11) 0.539 0.98 (0.83–1.16) 0.811
a Estimate is per additional pathogen for total pathogen burden and per tenfold increase in pathogen quantity for individual pathogens, and is adjusted for the week 6 OPV
serum  neutralizing titer.
b Additionally adjusted for gender, income, treatment of drinking water, weight-for-age Z score at 10 weeks, number of episodes of diarrhea through 6 weeks of age, weeks
o
ens de
a
t
i
e
F
i
f
ﬁ
sf  exclusive breastfeeding through week 18, and serum zinc level at 18 weeks.
c Total pathogen burden was deﬁned as the sum total of non-enterovirus pathog
djusted for possible risk factors for rotavirus diarrhea identiﬁed in
he primary analysis of RV effectiveness from the PROVIDE study
n children who received RV per protocol, including micronutri-
nts, nutritional status, breastfeeding and water treatment [34,35].
ollowing adjustment for confounders, EV quantity in stool was
ndependently associated with a lower rotavirus serum IgA titer,
ailure to seroconvert, and breakthrough rotavirus diarrhea in the
rst year of life (Table 4), while no association was seen for Sabin
train poliovirus quantity.tected at analytical cutoff of Ct < 35.
4. Discussion
The major ﬁnding of this paper is not only the conﬁrmation of the
deleterious role of NPEV on OPV and RV response, but the seemingly
selective role of NPEV versus other known enteropathogens, all of
which were interrogated with highly sensitive molecular diagnos-
tics. The only exception would appear to be Campylobacter species,
which was also associated with impaired OPV  immunogenicity.
An important feature of this work was  the quantitative analysis
3072 M.  Taniuchi et al. / Vaccine 34 (2016) 3068–3075
Fig. 2. Association between EV quantity and serum neutralizing antibody titers to serotype P1, P2, and P3. Enterovirus-negative samples are jittered on the x-axis.
Table 3
Association between speciﬁc pathogens in stools collected prior to ﬁrst Rotarix dose and serum anti-Rotavirus IgA titer at 18 weeks by linear regression (n = 159).
Pathogen Serum IgA titer Seroconversion
Change in log rotavirus serum IgA titera P value Odds ratio (95% CI)a P value
Adenovirus 40/41 0.06 0.698 1.06 (0.90–1.24) 0.486
Enterovirus −0.15 <0.001 0.93 (0.89–0.98) 0.004
Norovirus GI −0.02 0.741 0.96 (0.89–1.04) 0.322
Rotavirus 0.15 0.121 1.10 (0.99–1.22) 0.086
EAEC  −0.06 0.108 0.98 (0.94–1.02) 0.295
Atypical EPEC −0.05 0.563 0.95 (0.87–1.04) 0.266
ST-ETEC 0.02 0.836 1.03 (0.91–1.16) 0.665
a Estimate is per tenfold increase in pathogen quantity and is adjusted for the week 6 rotavirus serum IgA titer.
M. Taniuchi et al. / Vaccine 3
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between enteric infection and oral vaccine responses, something
that has not been done in historical studies because qPCR for such
a broad panel of infections was  not previously possible.
It has long been suspected that enterovirus infection could inter-
fere with oral polio vaccine performance. It has been postulated
that concurrent NPEV infection may  interfere with Sabin vaccine
uptake because receptors may  be conformation ally nearby on the
enterocyte, or NPEV may  induce antiviral immunity which then
prevents Sabin viruses from establishing an infection [11]. We  in
fact found an association of concurrent EV on OPV serum neutral-
izing response, particularly for P1. Additionally, we  observed an
association between Campylobacter quantity in stool prior to the
ﬁrst OPV administration and subsequent diminished OPV1-3 titers.
Few studies have examined the role of Campylobacter on OPV. In
the one relevant study of Mexican infants, Campylobacter culture
positivity was  not associated with a diminished response to the
ﬁrst OPV dose, but did contribute to an effect on OPV1 and 2 at
the second dose [7]. We have previously shown that Campylobac-
ter PCR is vastly more sensitive than culture, which may explain
some of this difference [36]. Whether Campylobacter infection is
a marker for other risk factors or directly causal to the impaired
OPV response requires additional study, such as through antibiotic
trials. We  would note that the Campylobacter effect was most signif-
icant for the P2 titer, which is the least problematic Sabin type, and
impaired P2 response also correlated generically with an increased
number of enteric infections. Therefore the P2 immunogenicity
lesion noted in this study may  reﬂect a small number of infants
with generally compromised immunity (to OPV2, Campylobacter,
and other infections).
Relatively less is understood about concurrent enteric infec-
tion on RV response, outside of direct OPV-RV co-administration
studies. These have been performed in a few countries, including
Bangladesh, with small sample sizes and various vaccine regimens,
but have generally shown a modestly reduced serum rotavirus
IgA titer or seroconversion rate after co-administration [5,8,37].
This can generally be overcome with multiple RV administrations
thus the clinical signiﬁcance of this observation has been uncer-
tain. The role of enteric infections other than OPV  on RV has been
even less studied. In vitro, however, competition studies with EV
and rotavirus have revealed preferential replication of EV, suggest-
ing such infections could impact RV response [38]. In this context,
our ﬁnding of the negative association between EV infection and
rotavirus IgA titer is novel, particularly since this association did
not track with OPV infection. Moreover, this NPEV effect on RV
was also seen clinically, with increases in breakthrough RV diar-
rhea in those with higher EV (but not OPV) quantity at the time of
the ﬁrst RV. The deleterious effect of EV on breakthrough diarrhea
held up against multivariable regression for potential confound-
ing risk factors for RV diarrhea, such as poverty, malnutrition, and
water quality. Evidence for a negative clinical impact on RV efﬁcacy
by concurrent enteric infections has eluded previous studies, prob-
ably because these have been performed in high or middle income
countries where concurrent infections and RV transmission is low
while immunogenicity is high [39].
As for possible interventions, the effect size of EV quantity on
immunogenicity and RV efﬁcacy did appear substantial compared
with other risk factors, so studies to evaluate EV prevention meas-
ures should be pursued. Unfortunately the genus is comprised of
12 species and 5 serotypes (coxsackievirus, echovirus, enterovirus,
rhinovirus, and poliovirus). These are ubiquitous, among the most
common viruses infecting humans, and spread person to person
via direct and indirect routes. Hygienic measures such as hand-
washing can prevent acquisition of certain strains [40], and it will
be valuable to evaluate if particular water, sanitation, and hygiene
interventions are effective in reducing EV burden and thus could
be expected to impact oral vaccine performance.
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There were limitations to this study. The study was  performed in
ne single site, where the exact proﬁle of risk factors for impaired
ral vaccine response may  not be generalizable. The sample size
as modest, we could not perform TAC on all stools at all time
oints, and thus the power to observe effects of rarer pathogens was
ow. However, associations between rare pathogens and impaired
ral vaccine performance would be unlikely to have signiﬁcant pub-
ic health implications. Detection of nucleic acid does not necessar-
ly denote replicating organism, however higher quantity infections
o correlate with culture positivity [14,33]. Another limitation is
hat we did not have serotype-speciﬁc polio neutralizing antibody
iters after each OPV administration nor rotavirus IgA titers after
accination at weeks 10 and 17, which would have enabled per-
osage examinations of titers. Because the pan-EV qPCR assay will
etect OPV, the identiﬁed associations with NPEV are based on the
ubtractive logic of an EV association without an OPV association.
irect discrimination of the panoply of enteroviruses by next gen-
ration sequencing will be required to further dissect and conﬁrm
his. In addition, the mechanisms by which NPEV impair the effec-
iveness of oral vaccines deserves further evaluation, particularly in
tudies which can compare the impact of NPEV in both vaccinated
nd unvaccinated children exposed to RV.
. Conclusions
In summary, our quantitative analysis of a broad spectrum
f enteric pathogens at the time of the ﬁrst OPV administration
hows that EV and Campylobacter quantity was associated with
ower immunogenicity. For the ﬁrst time, an association was also
een between EV carriage and both Rotarix immunogenicity and
fﬁcacy. Strategies to reduce EV transmission could complement
ther approaches to improving oral vaccine performance in these
ettings.
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